Verve Therapeutics Stock (NASDAQ:VERV)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$5.93

52W Range

$4.30 - $20.12

50D Avg

$5.40

200D Avg

$7.73

Market Cap

$511.98M

Avg Vol (3M)

$1.35M

Beta

1.81

Div Yield

-

VERV Company Profile


Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

255

IPO Date

Jun 17, 2021

Website

VERV Performance


VERV Financial Summary


Dec 23Dec 22Dec 21
Revenue$11.76M$1.94M-
Operating Income$-223.12M$-165.69M$-87.07M
Net Income$-200.07M$-157.39M$-118.64M
EBITDA$-217.67M$-162.88M$-87.07M
Basic EPS$-3.12$-8.87$-4.41
Diluted EPS$-3.12$-8.87$-4.41

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
SANASana Biotechnology, Inc.
ADPTAdaptive Biotechnologies Corporation
CRSPCRISPR Therapeutics AG
BPMCBlueprint Medicines Corporation
IPSCCentury Therapeutics, Inc.
NTLAIntellia Therapeutics, Inc.
EDITEditas Medicine, Inc.
PRMEPrime Medicine, Inc.
RLAYRelay Therapeutics, Inc.
CRBUCaribou Biosciences, Inc.
BEAMBeam Therapeutics Inc.
LIFEaTyr Pharma, Inc.